TSC22D2 Regulates ACOT8 to Delay the Malignant Progression of Colorectal Cancer
Nana Zhou,Chaoqin Guo,Jingyang Du,Xu Zhang,Qiuran Xu,Xiaoliang Zheng,Linglan Tu
DOI: https://doi.org/10.2147/ott.s449244
IF: 4
2024-03-05
OncoTargets and Therapy
Abstract:Nana Zhou, 1, &ast Chaoqin Guo, 1, &ast Jingyang Du, 1 Xu Zhang, 1 Qiuran Xu, 2 Xiaoliang Zheng, 3 Linglan Tu 3 1 School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, 310053, People's Republic of China; 2 The Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, People's Republic of China; 3 School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou, 310053, People's Republic of China &astThese authors contributed equally to this work Correspondence: Linglan Tu; Xiaoliang Zheng, School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou, Zhejiang, 310053, People's Republic of China, Tel +86-571-88215564 ; +86-571-88215569, Email ; Purpose: Colorectal cancer (CRC) is one of the cancers with high incidence and mortality rates worldwide. In China, there are approximately 400,000 new CRC cases each year, seriously endangering people's life and health. Transforming growth factor β-stimulated clone 22 domain family, member 2 (TSC22D2) is widely expression in cancers, but the role of TSC22D2 in CRC are still unknown. Methods: Real‐time quantitative PCR (qRT-PCR) and Western blot were applied to determine the TSC22D2 levels. CCK-8, colony formation and transwell assays were used to determine the proliferation and metastasis abilities of CRC cells in vitro. In vivo metastatic potential was assessed using a subcutaneously injected mouse model and. Western-blot and immunoprecipitation experiments were used to study the mechanism of TSC22D2‐mediated metastasis. Results: We found TSC22D2 was deregulated in CRC tissues and cells and implied poor prognosis. Overexpression TSC22D2 significantly promoted CRC cells proliferation and tumorigenicity both in vitro and vivo, whereas knockdown TSC22D2 resulted in the opposite effects. Importantly using a co-immunoprecipitation (co-IP) assay combined with mass spectrometry analysis to identify TSC22D2-interacting acyl-coenzyme A thioesterases 8 (ACOT8), TSC22D2 maintained stability of ACOT8. Overexpression of TCC22D2 in CRC cells can promote the expression of ACOT8 and inhibit the proliferation and metastasis of CRC cells through EMT mechanism, highlighting the possibility of TSC22D2 as a potential target in CRC development. Conclusion: In summary, the present study revealed the inhibitory effect of TSC22D2 on the proliferation of colorectal cancer cells, suggesting that TSC22D2 may be an important tumor suppressor and a potential therapeutic target during colorectal carcinogenesis. Keywords: colorectal cancer, TSC22D2, ACOT8, EMT Colorectal cancer is a human disease with high incidence and mortality rates, and is one of the most common malignant tumors worldwide. 1 With the improvement of people's living standards and changes in diet structure, the incidence rate of colorectal cancer is rapidly increasing. 2 At present, the treatment options for colorectal cancer mainly include surgical resection, radiotherapy, and palliative care. High nutrition and low fiber diet, genetic factors, and certain chronic intestinal diseases accompanied by intestinal mucosal hyperplasia are closely related to the onset of CRC. 3 According to the 2020 Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of colorectal cancer, molecular diagnosis of colorectal cancer mainly relies on the content of MMR protein, 4 mutation frequency of RAS, BARF genes, and gene fusion level of NTRK and Her2. 5,6 Although these measures have improved the accuracy of CRC diagnosis to some extent, the objective remission rate of CRC is still unsatisfactory. Therefore, better understanding of the molecular mechanisms of CRC will be beneficial for tumor typing and personalized treatment, and will improve the overall survival rate of CRC patients. There is increasing evidence that many TSC22D2 family proteins interact with other proteins to form macromolecular complexes and participate in a wide range of biological processes. For example, TSC-22 acts as a tumor suppressor by safeguarding p53 from poly-ubiquitination mediated-degradation. 7 TSC22D3 inhibits NF-κB nuclear translocation and DNA binding. 8 Sequencing analysis of a family's genes revealed that TSC22D2 is associated with various cancers. 9 Lower levels of TSC22D2 indicate a poor prognosis. 10 TSC22D2 is in the cytoplasm of eukaryotic cells and belongs to the leucine zipper transc -Abstract Truncated-
oncology,biotechnology & applied microbiology